Skip to search formSkip to main contentSkip to account menu

anti-CD137 monoclonal antibody

Known as: Anti-4-1BB Monoclonal Antibody, Immunoglobulin G4, Anti-(Human Receptor 4-1BB) (Human Gamma-Chain), Disulfide with Human Kappa-Chain, Dimer, URELUMAB 
A fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137… 
National Institutes of Health

Related topics

Related topics

6 relations
Antibody-Dependent Cellular CytotoxicityB-LymphocytesBMS-663513Cytotoxic T-Lymphocytes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract B026: Development of tumor-targeted agonistic Immunomodulators using the DARPin® technology platform
Background: Antibodies against several agonistic immunomodulatory receptors proved to be highly efficacious in preclinical tumor… 
2017
2017
Comparison of an FAP-targeted, CD137 activating DARPin drug candidate with a non-targeted, CD137 activating antibody in a human PBMC transplanted HT-29 mouse tumor model.
e14626Background: Urelumab (BMS-663513) is a humanized monoclonal antibody binding to CD137 which, upon Fc-clustering, leads to… 
2017
2017
Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma and the potential benefit of anti-CD137 stimulation.
e14545Background: Tumor specific TILs can be in vitro expanded and have the ability to induce complete and durable tumor… 
2016
2016
Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity
ABSTRACT Studies of sequential anti-CD137/anti-CD20 therapy have previously shown that the efficacy of anti-CD20 was heavily… 
2014
2014
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.
3017 Background: Anti-CD137 antibody was shown in both murine cancer models and in a first-in-human, phase I trial (Sznol et al… 
2014
2014
Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists
The past decade has been a period of tremendous progress in the area of cancer immunotherapy. The field has progressed from a… 
2013
2013
A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.
TPS3108 Background: CD137 (4-1BB) is a costimulatory molecule that belongs to the TNF superfamily. It is upregulated on activated… 
2012
2012
A formulation for the anti-4-7-antibody
Highly Cited
2007
Highly Cited
2007
Combined natural killer T-cell based immunotherapy eradicates established tumors in mice.
A rational monoclonal antibody (mAb)-based antitumor therapy approach has previously been shown to eradicate various established… 
Review
2006
Review
2006
Dual immunoregulatory pathways of 4-1BB signaling
It is perhaps rare to encounter among the various immunologically competent receptor–ligand pairs that a single cell surface… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)